secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0000950170-23-058627
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical licenses SCS Microinjector to BioCryst for avoralstat in DME
--------------------------------------------------------------------------------

- Clearside granted BioCryst exclusive worldwide license to use SCS Microinjector for avoralstat in diabetic macular edema.
- Upfront fee of $5.0 million; eligible for up to $30.0 million in clinical/regulatory milestones and $47.5 million in sales-based milestones.
- Tiered mid-single digit royalties on annual global net sales, highest rate on sales over $1.5 billion.
- BioCryst responsible for all development, regulatory, and commercialization; Clearside to supply SCS Microinjectors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023058627/0000950170-23-058627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023058627/clsd-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer